EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R‐GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.97_2631
Abstract: *Was employed by DRG Abacus at the time of analysis **Was employed by F. Hoffmann-La Roche Ltd at the time of the analysis Background: Despite improvements in DLBCL treatment, outcomes for patients with R/R DLBCL… read more here.
Keywords: sct ineligible; network; gemcitabine; analysis ... See more keywords
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-10-809210
Abstract: In diffuse large B-cell lymphoma (DLBCL), activation of the B-cell receptor (BCR) promotes multiple oncogenic signals, which are essential for tumor proliferation. Inhibition of the Bruton's tyrosine kinase (BTK), a BCR downstream target, is therapeutically… read more here.
Keywords: lymphoma; kinase; inhibition; cell receptor ... See more keywords
The Neutrophil-to-Lymphocyte Ratio Is Prognostic in Patients with Diffuse Large B-Cell Lymphoma: A Study from the Latin American Group of Lymphomas (GELL)
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113246
Abstract: Introduction: Diffuse large B-Cell Lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world. The IPI score is a powerful risk-stratification tool in patients with DLBCL. The neutrophil-to-lymphocyte ratio (NLR) has shown to… read more here.
Keywords: research; group; patients dlbcl; research funding ... See more keywords
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007779
Abstract: Key Points • The best response rates were observed with pembrolizumab before tisagenlecleucel; however, definitive conclusions cannot be made.• Pembrolizumab did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion in the day… read more here.
Keywords: tisagenlecleucel plus; pembrolizumab patients; plus pembrolizumab; safety efficacy ... See more keywords
Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s386562
Abstract: Purpose Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignant lymphoid neoplasm and is the most common subtype of non-Hodgkin lymphoma in adults. More than half of patients with DLBCL can achieve remission with standard… read more here.
Keywords: overexpression; bcl2 bcl6; bcl6 vegfr1; patients dlbcl ... See more keywords
A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.953808
Abstract: Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma subtype worldwide and occurs frequently in the elderly population. However, there are limited data on the clinical profiles of patients with DLBCL over… read more here.
Keywords: 239 patients; cell lymphoma; patients dlbcl; large cell ... See more keywords